CytoDyn Inc. (CYDY)
OTCMKTS · Delayed Price · Currency is USD
0.2730
-0.0114 (-4.01%)
Jul 29, 2025, 3:59 PM EDT
CytoDyn Employees
CytoDyn had 9 employees as of May 31, 2024. The number of employees decreased by 3 or -25.00% compared to the previous year.
Employees
9
Change (1Y)
-3
Growth (1Y)
-25.00%
Revenue / Employee
n/a
Profits / Employee
$416,111
Market Cap
355.85M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
May 31, 2024 | 9 | -3 | -25.00% |
May 31, 2023 | 12 | -11 | -47.83% |
May 31, 2022 | 23 | -1 | -4.17% |
May 31, 2021 | 24 | 5 | 26.32% |
May 31, 2020 | 19 | 9 | 90.00% |
May 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
May 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
May 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
May 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
May 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
Endo, Inc. | 3,116 |
Tian'an Technology Group | 8 |
Elite Pharmaceuticals | 68 |
Glass House Brands | 374 |
Northwest Biotherapeutics | 25 |
American Oncology Network | 1,914 |
Silence Therapeutics | 116 |
CytoDyn News
- 4 days ago - CytoDyn files $100M mixed securities shelf - Seeking Alpha
- 4 weeks ago - CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab - GlobeNewsWire
- 5 weeks ago - CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer - GlobeNewsWire
- 2 months ago - A Penny Stock To Watch In Challenging Cancer Space - Benzinga
- 2 months ago - CytoDyn Releases ESMO Breast Cancer Meeting Poster - GlobeNewsWire
- 2 months ago - CytoDyn highlights potential of lead drug against solid tumors with new data - Seeking Alpha
- 2 months ago - CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors - GlobeNewsWire
- 3 months ago - CytoDyn appoints Robert Hoffman as CFO - Seeking Alpha